acut
respiratori
infect
seriou
infect
respons
approxim
million
death
per
year
one
lead
caus
morbid
mortal
worldwid
acut
respiratori
infect
categor
either
upper
lower
respiratori
infect
caus
wellrecognis
viral
pathogen
includ
limit
influenza
viru
type
b
parainfluenza
viru
respiratori
syncyti
viru
rsv
metapneumoviru
type
b
coronaviru
rhinoviru
enteroviru
reoviru
bocaviru
adenoviru
bacteri
pathogen
primarili
streptococcu
pneumonia
haemophilu
influenza
influenza
acut
viral
respiratori
infect
affect
global
adult
popul
per
year
result
approxim
million
death
million
case
sever
ill
worldwid
annual
influenzalik
ill
ili
consid
subset
acut
respiratori
infect
result
sudden
onset
symptom
fever
bodi
temperatur
greater
cough
sore
throat
patient
physician
difficulti
treatment
ili
determin
aetiolog
gener
possibl
sole
clinic
basi
current
pharmacolog
intervent
prevent
treatment
respiratori
viral
infect
primarili
limit
vaccin
antivir
influenza
avail
antivir
treatment
influenza
infect
ion
channel
inhibitor
eg
amantadin
rimantadin
neuraminidas
inhibitor
eg
oseltamivir
zanamivir
infect
caus
bacteri
pathogen
treatment
involv
antibiot
also
medic
provid
symptomat
relief
howev
case
viral
aetiolog
medic
symptomat
treatment
provid
vaccin
season
influenza
remain
one
standard
approach
prevent
diseas
howev
immunis
rate
season
influenza
remain
low
mani
european
countri
even
though
influenza
vaccin
part
nation
immunis
schedul
countri
moreov
vaccin
effect
circul
influenza
virus
given
season
similar
virus
includ
influenza
vaccin
vaccin
offer
clinic
benefit
pathogen
circul
season
inappropri
use
antibiot
treatment
acut
respiratori
infect
observ
winter
month
even
though
major
infect
caus
viral
pathogen
selflimit
practic
may
result
side
effect
develop
antibiot
resist
pathogen
well
increas
cost
burden
healthcar
system
inosin
pranobex
combin
pacetamidobenzo
salt
n
inosin
molar
ratio
immunomodulatori
antivir
drug
licens
sinc
sever
countri
worldwid
treatment
viral
infect
inosin
pranobex
stimul
nonspecif
immun
respons
independ
specif
viral
antigen
respons
ili
clinic
studi
inosin
pranobex
shown
induc
type
helper
celltyp
respons
mitogen
antigenactiv
cell
respons
initi
tlymphocyt
matur
differenti
potenti
induc
lymphoprolif
respons
similarli
drug
modul
tlymphocyt
natur
killer
cell
cytotox
suppressor
helper
cell
function
increas
number
immunoglobulin
g
complement
surfac
marker
inosin
pranobex
also
increas
cytokin
interleukin
il
product
product
upregul
express
receptor
vitro
safeti
profil
inosin
pranobex
establish
clinic
trial
sever
indic
popul
rapid
increas
number
mononuclear
cell
first
dose
inosin
pranobex
observ
subject
increas
consist
clinic
observ
rapid
resolut
common
cold
symptom
phase
studi
aim
compar
efficaci
safeti
inosin
pranobex
placebo
subject
laboratoryconfirm
acut
respiratori
viral
infect
order
evalu
clinic
use
inosin
pranobex
treatment
acut
respiratori
viral
infect
primari
efficaci
endpoint
comparison
inosin
pranobex
placebo
group
term
time
resolut
influenzalik
symptom
present
baselin
none
subgroup
analysi
subject
clinic
diagnos
ili
studi
evalu
efficaci
inosin
pranobex
compar
placebo
healthi
without
relat
ongo
diseas
subject
less
year
age
least
year
age
studi
also
evalu
effect
bodi
mass
index
bmi
subject
less
year
age
nonobes
bmi
obes
bmi
addit
studi
evalu
efficaci
inosin
pranobex
subject
less
year
age
time
resolut
influenzalik
symptom
present
baselin
mild
none
ie
score
influenzalik
symptom
assess
scale
phase
randomis
placebocontrol
doubleblind
multicentr
studi
subject
clinic
diagnos
ili
includ
subject
laboratoryconfirm
acut
respiratori
viral
infect
due
influenza
b
viru
rsv
adenoviru
parainfluenza
viru
studi
conduct
studi
site
czech
republ
studi
site
slovakia
studi
site
enrol
occur
decemb
april
last
subject
visit
june
detail
primari
efficaci
endpoint
provid
addit
file
male
nonpregn
femal
subject
age
year
clinic
diagnosi
ili
includ
studi
influenzalik
ill
defin
oral
temperatur
least
observ
studi
site
least
respiratori
symptom
cough
sore
throat
nasal
obstruct
least
constitut
symptom
fatigu
headach
myalgia
feverish
respiratori
constitut
symptom
requir
consid
subject
moder
sever
intens
score
influenzalik
symptom
assess
scale
subject
requir
experienc
onset
ili
h
prior
screen
onset
defin
time
subject
experienc
fever
least
respiratori
symptom
least
constitut
symptom
full
inclus
criteria
influenzalik
symptom
assess
scale
detail
addit
file
subject
exclud
particip
studi
met
follow
criteria
immunosuppress
disord
receiv
immunosuppress
therapi
undergo
treatment
xanthin
oxidas
inhibitor
uricosur
agent
treatment
thiazid
loop
diuret
chronic
renal
dysfunct
sever
liver
function
impair
lactos
intoler
cancer
nonremiss
stage
undergo
treatment
zidovudin
pregnant
lactatingbreastfeed
receiv
dose
inosin
pranobex
oseltamivir
zanamivir
amantadin
rimantadin
occurr
ili
administ
investig
drug
investig
vaccin
within
day
prior
screen
detail
exclus
criteria
provid
addit
file
sampl
size
subject
subject
treatment
group
modifi
intenttotreat
mitt
analysi
set
total
randomli
assign
subject
calcul
use
logrank
test
input
median
surviv
time
sampl
size
calcul
perform
use
pass
softwar
version
ncss
llc
kaysvil
utah
usa
consid
statist
power
detect
clinic
relev
differ
day
treatment
group
day
placebo
group
dropout
rate
also
consid
meant
final
sampl
size
subject
subject
treatment
group
would
requir
studi
howev
challeng
face
enrol
includ
late
influenza
alert
unexpectedli
mild
influenza
season
decis
made
continu
enrol
april
total
subject
randomli
assign
subject
met
criteria
inclus
mitt
analysi
set
analys
conduct
use
softwar
version
sa
institut
inc
cari
north
carolina
usa
statist
test
hypothesi
test
perform
level
signific
result
confid
interv
ci
adjust
multipl
made
hazard
ratio
hr
ci
estim
use
proport
hazard
model
hr
indic
benefit
inosin
pranobex
compar
placebo
safeti
analysi
set
consist
subject
receiv
least
dose
studi
drug
analys
use
safeti
analysi
set
group
subject
accord
treatment
subject
actual
receiv
mitt
analysi
set
consist
randomli
assign
subject
posit
laboratori
confirm
acut
respiratori
viral
infect
due
influenza
b
viru
rsv
adenoviru
parainfluenza
viru
set
use
primari
secondari
efficaci
analys
detail
primari
efficaci
endpoint
provid
addit
file
analys
use
mitt
analysi
set
group
subject
accord
randomis
treatment
intenttotreat
itt
analysi
set
includ
subject
randomli
assign
receiv
doubleblind
studi
drug
use
subgroup
analys
day
elig
subject
randomli
assign
receiv
either
inosin
pranobex
placebo
alloc
ratio
stratif
activ
drug
match
placebo
tablet
provid
ident
carton
identifi
kit
number
studi
site
staff
subject
remain
blind
throughout
studi
personnel
access
interact
web
respons
system
clinic
suppli
unblind
access
treatment
assign
parti
involv
studi
fulli
blind
inosin
pranobex
placebo
tablet
selfadminist
subject
day
tablet
oral
time
daili
first
dose
taken
immedi
randomis
studi
site
remain
dose
selfadminist
home
dose
taken
approxim
h
apart
consist
subject
lifestyl
ie
schedul
dose
disturb
subject
usual
sleep
pattern
subject
provid
kit
contain
randomis
medic
suffici
subject
day
treatment
subject
instruct
consum
tablet
specifi
durat
requir
return
excess
studi
drug
tablet
endoftreat
eot
visit
adher
studi
drug
administr
good
monitor
part
studi
total
studi
durat
day
day
subject
consist
dose
period
day
day
day
eot
visit
day
day
followup
period
day
day
eot
visit
prior
randomis
day
nasopharyng
swab
sampl
collect
test
presenc
influenza
b
viru
rsv
adenoviru
parainfluenza
viru
use
appropri
polymeras
chain
reaction
analys
result
use
identifi
subject
includ
mitt
set
consequenti
identifi
subject
includ
primari
endpoint
analysi
detail
procedur
studi
visit
includ
addit
file
primari
efficaci
endpoint
time
resolut
influenzalik
symptom
present
baselin
none
ie
score
defin
complet
absenc
symptom
influenzalik
symptom
assess
scale
detail
provid
addit
file
secondari
endpoint
includ
time
resolut
respiratori
symptom
cough
sore
throat
nasal
obstruct
time
absenc
fever
oral
temperatur
least
consecut
read
least
h
apart
time
resumpt
normal
activ
ie
score
daili
activ
assess
scale
frequenc
viral
respiratori
infect
complic
defin
hospitalis
death
due
ili
complic
ili
requir
antibiot
treatment
secondari
bacteri
infect
subgroup
analysi
conduct
time
resolut
influenzalik
symptom
present
baselin
none
subject
clinic
diagnos
ili
conduct
subject
less
year
age
subject
least
year
age
without
relat
ongo
diseas
relat
ongo
diseas
medic
condit
prefer
term
asthma
bronchiti
chronic
bronchiti
chemic
bronchiti
ongo
start
studi
addit
analysi
conduct
subject
less
year
age
nonobes
bmi
obes
bmi
addit
analysi
conduct
time
resolut
influenzalik
symptom
mild
none
subject
less
year
age
safeti
evalu
studi
analysi
advers
event
ae
vital
sign
physic
examin
studi
perform
accord
ethic
principl
origin
declar
helsinki
intern
council
harmon
applic
regul
studi
approv
studi
start
two
multicentr
ethic
committe
mec
one
mec
univers
hospit
brno
approv
studi
studi
centr
czech
republ
second
one
mec
region
offic
approv
studi
studi
centr
slovakia
potenti
subject
sign
inform
consent
form
prior
randomis
day
studyrel
procedur
perform
detail
demograph
baselin
characterist
present
addit
file
demograph
characterist
similar
treatment
group
overal
mean
age
year
overal
mean
bmi
rang
major
subject
studi
less
year
age
baselin
subject
present
least
influenzalik
symptom
cough
sore
throat
nasal
obstruct
fatigu
headach
myalgia
feverish
score
sever
medic
histori
report
subject
inosin
pranobex
treatment
group
subject
placebo
group
commonli
report
medic
histori
vascular
disord
surgic
medic
procedur
medic
histori
gastrointestin
disord
inosin
pranobex
group
placebo
group
hepatobiliari
disord
inosin
pranobex
group
placebo
group
also
report
overal
mean
report
dose
complianc
high
similar
treatment
group
treatment
group
major
subject
treatment
group
dose
complianc
rang
inosin
pranobex
n
placebo
n
differ
time
resolut
influenzalik
symptom
treatment
group
statist
signific
show
trend
toward
improv
subject
inosin
pranobex
group
compar
subject
placebo
group
hr
ci
p
fig
substanti
decreas
proport
subject
influenzalik
symptom
observ
inosin
pranobex
group
day
decreas
similar
proport
occur
day
subject
placebo
group
differ
time
resolut
secondari
endpoint
also
show
similar
trend
toward
improv
subject
inosin
pranobex
group
compar
subject
placebo
group
secondari
endpoint
differ
signific
detail
result
provid
addit
file
subgroup
analysi
subject
less
year
age
without
relat
ongo
diseas
differ
time
resolut
influenzalik
symptom
treatment
group
statist
signific
p
show
faster
improv
subject
inosin
pranobex
group
compar
subject
placebo
group
hr
ci
fig
tabl
howev
subject
least
year
age
without
relat
ongo
diseas
differ
time
resolut
influenzalik
symptom
treatment
group
statist
signific
ci
p
nonobes
bmi
subject
less
year
age
differ
time
resolut
influenzalik
symptom
treatment
group
statist
signific
p
show
faster
improv
subject
inosin
pranobex
group
compar
subject
placebo
group
hr
ci
howev
obes
bmi
subject
less
year
age
differ
time
resolut
influenzalik
symptom
treatment
group
statist
signific
hr
ci
p
subject
less
year
age
differ
time
resolut
influenzalik
symptom
mild
none
treatment
group
statist
signific
p
show
faster
improv
subject
inosin
pranobex
group
compar
subject
placebo
group
hr
ci
proport
subject
experienc
treatmentemerg
ae
teae
number
teae
lower
inosin
pranobex
group
subject
teae
placebo
group
subject
teae
common
teae
report
subject
either
treatment
group
bacteri
superinfect
inosin
pranobex
n
placebo
n
diarrhoea
inosin
pranobex
n
placebo
n
teae
report
subject
either
treatment
group
major
teae
mild
moder
sever
unrel
studi
drug
opinion
investig
overal
sever
teae
report
subject
sever
teae
rhinopharyng
maxillari
sinus
vertebrogen
pain
syndrom
report
subject
inosin
pranobex
group
sever
teae
pleuropneumonia
report
subject
placebo
group
death
report
studi
overal
subject
inosin
pranobex
group
subject
placebo
group
experienc
teae
led
studi
drug
discontinu
three
treatmentemerg
seriou
ae
sae
report
subject
sever
rhinopharyng
sever
vertebrogen
syndrom
report
subject
inosin
pranobex
group
subject
placebo
group
report
sever
pleuropneumonia
sae
result
perman
discontinu
studi
drug
discontinu
subject
studi
sae
resolv
none
sae
opinion
investig
relat
studi
drug
mean
chang
vital
sign
physic
examin
valu
baselin
small
clinic
signific
trend
observ
treatment
group
pregnanc
report
studi
phase
randomis
placebocontrol
doubleblind
multicentr
studi
evalu
efficaci
inosin
pranobex
subject
clinic
diagnos
ili
includ
subject
laboratoryconfirm
acut
respiratori
viral
infect
due
influenza
b
viru
rsv
adenoviru
parainfluenza
viru
studi
also
evalu
efficaci
inosin
pranobex
subgroup
subject
less
year
age
without
relat
diseas
asthma
bronchiti
chronic
bronchiti
chemic
bronchiti
nonobes
bmi
obes
bmi
well
subgroup
subject
least
year
age
without
relat
ongo
diseas
addit
subgroup
analysi
conduct
subject
less
year
age
time
resolut
influenzalik
symptom
mild
none
current
studi
analysi
primari
endpoint
time
resolut
influenzalik
symptom
show
faster
improv
subject
treat
inosin
pranobex
compar
subject
administ
placebo
although
differ
treatment
group
reach
threshold
statist
signific
result
similar
secondari
efficaci
endpoint
time
resolut
respiratori
symptom
cough
sore
throat
nasal
obstruct
time
absenc
fever
time
resumpt
normal
activ
differ
occurr
viral
respiratori
infect
complic
treatment
group
statist
signific
immunosenesc
ie
agerel
declin
immun
system
obes
play
import
role
efficaci
immun
respons
pathogen
older
subject
show
diminish
immun
respons
pathogen
increas
risk
sever
infect
compromis
abil
adequ
combat
viral
infect
phenomenon
observ
splitviru
influenza
vaccin
low
respons
vaccin
observ
older
adult
wherea
vaccin
effect
younger
subject
low
respons
result
increas
suscept
influenza
associ
complic
older
adult
compar
younger
adult
typic
benefit
higher
respons
obes
also
identifi
independ
risk
factor
increas
suscept
influenza
viru
infect
suscept
result
diminish
tcell
respons
lower
influenza
vaccin
antibodi
level
obes
may
also
increas
risk
pneumonia
infect
restrict
lung
volum
immunosenesc
obes
bia
efficaci
studi
impair
respons
immun
system
pathogen
risk
complic
increas
individu
subgroup
analysi
current
studi
subject
less
year
age
without
relat
ongo
diseas
less
year
age
nonobes
bmi
statist
signific
differ
time
resolut
influenzalik
symptom
favour
inosin
pranobex
group
placebo
group
statist
signific
differ
observ
inosin
pranobex
placebo
group
subject
least
year
age
without
relat
ongo
diseas
subject
less
year
age
obes
bmi
thu
efficaci
inosin
pranobex
improv
nonobes
subject
compar
obes
subject
probabl
immun
system
former
capabl
defend
pathogen
neg
affect
obesityrel
complic
older
patient
decreas
immun
respons
pathogen
result
immunosenesc
therefor
may
take
longer
recov
ill
influenza
antiinfluenza
drug
may
effect
addit
analysi
subject
less
year
age
statist
signific
differ
time
resolut
influenzalik
symptom
mild
none
favour
inosin
pranobex
group
placebo
group
thu
indic
improv
symptom
better
inosin
pranobex
placebo
subset
subject
hr
ci
substanti
decreas
proport
subject
influenzalik
symptom
observ
inosin
pranobex
group
day
decreas
similar
proport
occur
day
subject
placebo
group
differ
could
result
time
necessari
activ
immun
system
inosin
pranobex
act
indirectli
stimul
immun
system
directli
attenu
symptom
result
also
consist
result
observ
studi
healthi
volunt
inosin
pranobex
show
immunomodul
properti
increas
serum
level
tumour
necrosi
day
approv
dose
treatment
durat
inosin
pranobex
two
tablet
oral
time
daili
use
studi
administ
treatment
vari
accord
weight
symptom
durat
subgroup
analysi
posolog
inosin
pranobex
gday
oral
studi
suitabl
subject
less
year
age
without
relat
ongo
diseas
subject
less
year
age
nonobes
bmi
certain
subject
least
year
age
obes
differ
dose
strategi
could
appropri
vari
dose
regimen
requir
evalu
use
placeboonli
group
studi
justifi
ili
gener
mild
selflimit
treatment
approv
acut
respiratori
viral
infect
influenza
addit
use
influenzaspecif
antivir
neuraminidas
inhibitor
amantadin
compon
routin
medic
manag
ili
mani
countri
includ
countri
studi
conduct
perform
highqual
efficaci
trial
ili
challeng
epidemiolog
consider
influenza
outbreak
period
influenza
season
predict
advanc
vari
year
year
furthermor
enrol
subject
symptom
present
less
h
necessari
first
h
period
maxim
viral
replic
antivir
medic
expect
benefit
time
current
studi
anticip
perform
influenza
season
northern
hemispher
octob
april
enrol
requir
number
subject
group
timefram
howev
enrol
challeng
could
commenc
low
attack
rate
start
late
alert
issu
nation
public
health
author
first
week
decemb
regard
statist
higher
incid
acut
respiratori
viral
infect
low
densiti
circul
virus
present
end
januari
result
enrol
subject
april
order
maxim
number
complet
subject
approxim
randomis
subject
expect
posit
laboratori
confirm
acut
respiratori
tract
infect
howev
subject
met
criteria
inclus
mitt
analysi
set
subject
fewer
subject
expect
effect
absenc
signific
influenza
outbreak
advers
affect
statist
power
thu
reduc
power
studi
could
potenti
explain
lack
statist
signific
primari
secondari
efficaci
endpoint
slightli
longer
durat
treatment
differ
dose
strategi
may
influenc
observ
efficaci
inosin
pranobex
proof
therapeut
effect
requir
high
attack
rate
ie
higher
number
sick
patient
one
influenza
season
attack
rate
difficult
predict
studi
adjust
sampl
size
calcul
account
possibl
belowaverag
flu
season
studi
longer
durat
eg
includ
influenza
season
account
lower
predict
attack
rate
necessari
achiev
desir
result
addit
enrol
subject
inosin
pranobex
group
report
medic
histori
gastrointestin
disord
report
hepatobiliari
disord
pharmacokinet
paramet
measur
studi
possibl
presenc
disord
baselin
may
affect
absorpt
distribut
metabol
studi
drug
may
influenc
studi
result
includ
efficaci
result
furthermor
age
comorbid
obes
enrol
subject
particularli
subject
year
age
may
also
affect
outcom
studi
safeti
analysi
demonstr
inosin
pranobex
treatment
well
toler
major
differ
safeti
profil
observ
treatment
group
treatmentemerg
sae
report
subject
none
consid
relat
studi
drug
investig
subject
die
studi
signific
chang
observ
vital
sign
physic
examin
either
studi
group
studi
result
indic
safeti
inosin
pranobex
treatment
subject
confirm
acut
respiratori
viral
infect
confirm
efficaci
inosin
pranobex
versu
placebo
healthi
nonobes
subject
less
year
age
clinic
diagnos
influenzalik
ill
result
studi
affect
epidemiolog
consider
includ
late
influenza
alert
low
densiti
circul
virus
studi
may
import
defin
predictor
treatment
success
includ
potenti
differ
dose
strategi
certain
patient
popul
underli
condit
may
impact
drug
plasma
level
relat
drug
effect
